![](https://monteverdelaw.com/wp-content/uploads/case-logo/juniper-pharmaceuticals-inc.jpg)
We are investigating the sale of Juniper Pharmaceuticals, Inc. (“Juniper” or the “Company”) (JNP) to Catalent Inc. (CTLT) (“Catalent”). Under the terms of the transaction, Juniper shareholders will receive $11.50 for each share of Juniper common stock that they own.